BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia.
Saved in:
| Title: | BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia. |
|---|---|
| Authors: | Robert F; Department of Medical Genetics, Level 6 Addenbrooke's Treatment Centre, Cambridge Biomedical Research Campus, Box 238, Cambridge , CB2 0QQ, UK. fr392@cam.ac.uk.; Early Cancer Institute, Department of Oncology, Cambridge Biomedical Research Campus, Hutchison Research Centre, Box 197, Cambridge, CB2 0XZ, UK. fr392@cam.ac.uk., Badja C; Department of Medical Genetics, Level 6 Addenbrooke's Treatment Centre, Cambridge Biomedical Research Campus, Box 238, Cambridge , CB2 0QQ, UK.; Early Cancer Institute, Department of Oncology, Cambridge Biomedical Research Campus, Hutchison Research Centre, Box 197, Cambridge, CB2 0XZ, UK., Boushaki S; Department of Medical Genetics, Level 6 Addenbrooke's Treatment Centre, Cambridge Biomedical Research Campus, Box 238, Cambridge , CB2 0QQ, UK.; Early Cancer Institute, Department of Oncology, Cambridge Biomedical Research Campus, Hutchison Research Centre, Box 197, Cambridge, CB2 0XZ, UK., Degasperi A; Department of Medical Genetics, Level 6 Addenbrooke's Treatment Centre, Cambridge Biomedical Research Campus, Box 238, Cambridge , CB2 0QQ, UK.; Early Cancer Institute, Department of Oncology, Cambridge Biomedical Research Campus, Hutchison Research Centre, Box 197, Cambridge, CB2 0XZ, UK., Memari Y; Department of Medical Genetics, Level 6 Addenbrooke's Treatment Centre, Cambridge Biomedical Research Campus, Box 238, Cambridge , CB2 0QQ, UK.; Early Cancer Institute, Department of Oncology, Cambridge Biomedical Research Campus, Hutchison Research Centre, Box 197, Cambridge, CB2 0XZ, UK., Momen S; Department of Medical Genetics, Level 6 Addenbrooke's Treatment Centre, Cambridge Biomedical Research Campus, Box 238, Cambridge , CB2 0QQ, UK.; Early Cancer Institute, Department of Oncology, Cambridge Biomedical Research Campus, Hutchison Research Centre, Box 197, Cambridge, CB2 0XZ, UK., Roumeliotis TI; Functional Proteomics Group, Institute of Cancer Research, Chester Betty Labs, London, SW3 6JB, UK., Kozik Z; Functional Proteomics Group, Institute of Cancer Research, Chester Betty Labs, London, SW3 6JB, UK., Gozdecka M; Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, CB2 0AW, UK., Choudhary J; Functional Proteomics Group, Institute of Cancer Research, Chester Betty Labs, London, SW3 6JB, UK., Vassiliou G; Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, CB2 0AW, UK., Koh GC; Department of Medical Genetics, Level 6 Addenbrooke's Treatment Centre, Cambridge Biomedical Research Campus, Box 238, Cambridge , CB2 0QQ, UK.; Early Cancer Institute, Department of Oncology, Cambridge Biomedical Research Campus, Hutchison Research Centre, Box 197, Cambridge, CB2 0XZ, UK., Nik-Zainal S; Department of Medical Genetics, Level 6 Addenbrooke's Treatment Centre, Cambridge Biomedical Research Campus, Box 238, Cambridge , CB2 0QQ, UK.; Early Cancer Institute, Department of Oncology, Cambridge Biomedical Research Campus, Hutchison Research Centre, Box 197, Cambridge, CB2 0XZ, UK. |
| Source: | Annals of hematology [Ann Hematol] 2026 Jan 19; Vol. 105 (1), pp. 32. Date of Electronic Publication: 2026 Jan 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
